Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Safer Pregnancy Alliance [OSPREA] and the Oxford Vaccine Group [OVG] have recently undertaken a successful recruitment drive for a study of maternal immunisation to prevent infant Respiratory Syncytial Virus [RSV] infection.

This is the first collaboration of its kind in Oxford, and the support provided by the Clinical Research Network Thames Valley and South Midlands has contributed to Oxford being the highest recruiting centre in the United Kingdom for this multinational, multi-centre study.

Babies born to participating mothers will now be followed up by paediatric staff at the Oxford Vaccine Group over winter to see if maternal immunisation is able to protect against this common but potentially life threatening virus. Particular credit should go to all the nurses, doctors, midwives and support staff of the two research teams, and it is expected that this will be the first of many such collaborations.